EXOZYMES INC. entered into Underwriting Agreement with MDB Capital valued at approximately $5,330,430 (effective 2026-06-05).
“On June 5, 2026, eXoZymes Inc. (the “Company”) entered into (i) an Underwriting Agreement (the “Underwriting Agreement”), dated as of June 5, 2026, with MDB Capital (“MDB”), as the sole underwriter and book runner, pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten offering (the “Offering”) an aggregate of 592,270 shares of common stock (the “Shares”), $0.000001 par value per share (the “Common Stock”), of the Company and 292,135 warrants to purchase up to an aggregate of 292,135 shares of Common Stock (the “Warrants”).”
Christopher A. Marlett was appointed as Chairman of the Board at EXOZYMES INC..
“The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.”
Edgardo Rayo was appointed as member of the Board at EXOZYMES INC..
“On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation.”
Mohammad Hayat resigned as President and Chairman at EXOZYMES INC..
“On February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors (the “ Board ”) of eXoZymes Inc., a Nevada corporation (the “ Company ”), as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.